Researchers in this trial are trying to find better ways of treating platinum-resistant ovarian cancer. Platinum resistance means your cancer no longer responds to platinum-based chemotherapy (e.g. carboplatin). Strong evidence suggests that cortisol, a hormone in your body, can affect how well certain cancer treatments work. Scientists have fou…

This trial is for those with a diagnosis of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer that has become resistant to platinum-based therapy. It is an open label study, which means that both you and your doctor will know what treatment you are receiving.The researchers conducting the trial are testing a new treatment ca…

Researchers in this study are trying to find out if treating platinum resistant ovarian cancer with an immunotherapy drug called embrolizumab and the chemotherapy drug paclitaxel is better than just treating with paclitaxel on it’s own. Platinum resistance means that your cancer no longer responds to platinum based chemotherapy (e.g carboplatin). …

The purpose of this study is to determine if a combination of two different anti-cancer drugs are safe and effective in treating different types of solid tumours, including ovarian cancer. It's for women with ovarian cancer whose cancer has continued to spread and grow despite standard chemotherapy treatments. The drugs involved in this trial are k…

In cases where ovarian, fallopian tube or peritoneal cancer has come back (recurrence or relapse) and it has become resistant to platinum-based chemotherapy, new treatment strategies and new drugs are needed to better treat this disease. This study tests a new drug both in combination with a known treatment and alone, to find out if the differe…

The main purpose of conducting the trial is to: determine the safety of combining cediranib, a VEGF inhibitor, with paclitaxel a weekly chemotherapy regime find out how well the treatment works in terms of shrinking the cancer and preventing bowel obstruction. If the cancer responds to this treatment then after the course of paclitaxel…